Esperion Therapeutics | ESPR - Ebit


Esperion Therapeutics reported $-16.03M in EBIT for its fiscal quarter ending in September of 2024.





Ebit Change Date
AbbVie USD 5.81B 4.36B Dec/2025
Alnylam Pharmaceuticals USD -29.96M 34.85M Sep/2025
Alterity Therapeutics Limited AUD -7.77M 2.99M Jun/2023
Amarin USD -1.7M 8.47M Sep/2025
Amgen USD 3.96B 464M Dec/2025
Biogen USD 659.6M 157M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Cipla INR 9.77B 6.21B Dec/2025
CSL USD 2.75B 1.35B Dec/2024
Cytokinetics USD -166.76M 55.25M Sep/2025
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Eli Lilly USD 8.99B 1.57B Dec/2025
Esperion Therapeutics USD -16.03M 11.51M Sep/2024
Geron USD -13.89M 1.43M Sep/2025
Grifols EUR 411.56M 15.51M Sep/2025
Halozyme Therapeutics USD 217.92M 15.48M Sep/2025
Heron Therapeutics USD -4.46M 5.76M Sep/2024
Ionis Pharmaceuticals USD -160.18M 304.96M Sep/2025
Merck USD 6.24B 1.32B Dec/2025
Minerva Neurosciences USD -4.37M 1.71M Sep/2024
Moderna USD -260M 557M Sep/2025
Nektar Therapeutics USD -34.34M 3.68M Sep/2024
Pfizer USD 4.65B 71M Dec/2025
PTC Therapeutics USD 3.49M 38.35M Sep/2025
Puma Biotechnology USD -2.2M 11.41M Jun/2024
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
United Therapeutics USD 389.3M 112.4M Sep/2025
Vanda Pharmaceuticals USD -10.28M 721K Dec/2024